Subscribe to our Newsletter
Be the first to know about every G4A opportunity!
Sign up for our newsletter and get more of G4A straight to your inbox.
“Oxygen. Everything needs it: bones, muscle, and even, while it calls the earth it’s home, the soul.” - Mary Oliver from Thirst
The poetry isn’t lost on scientists. Oxygen is the life-force that fuels the complex human body. Each bodily system relies on it, and on each other in turn. And Lung Disease, unfortunately, attacks the very core of it.
In the last three years, the Digital Therapeutics space has exploded. Positioned as a non-invasive and data-driven approach to health and care, it’s easy to see why. But the big question on everyone’s mind is whether Digital Therapeutics (DTx) is in collaboration or competition with the Pharma industry. A few months ago, I got to the spend the day at DTx West in San Mateo, CA, where I spoke on a panel on precisely this topic - Pharma and DTx: A Match Made In Heaven? - and was in good company alongside Sanofi, Sandoz, and Genentech.
Paris: the City of Lights. And of tech? Yes, as it turns out. As no stranger to innovation, Paris earned their lit-up nickname for being one of the first cities to install electricity. When Tech Tour brought their investor-focused conference to Paris last year, we knew we had to be there. Tech Tour is unique in that, at each tour stop, they exclusively showcase local talent and cover a variety of tech sectors - everything from healthcare, bio tech, clean tech, med tech, and more. We at G4A were excited to see what emerging technologies would await us.
Heart failure costs Americans $30.7 billion each year in treatment, medications, and missed work, making it the most expensive condition to treat (Business Insider). Despite these major impacts, heart health can easily go overlooked, often for years.